Showing results (131-140 of 172) with videos related to
Sort By:
Pageof 18
Cell|January 27, 2007
FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasisJi-Hye Paik, Ramya Kollipara, Gerald Chu, et al.Nature Genetics|March 17, 2009
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasmsOuti Kilpivaara, Semanti Mukherjee, Alison M Schram, et al.The New England Journal of Medicine|February 3, 2007
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosisLinda M Scott, Wei Tong, Ross L Levine, et al.Cancer Research|November 15, 2012
STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2Winnie F Tam, Patricia S Hähnel, Andrea Schüler, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 6, 2010
Transcriptional profiling of polycythemia vera identifies gene expression patterns both dependent and independent from the action of JAK2V617FWindy Berkofsky-Fessler, Monica Buzzai, Marianne K-H Kim, et al.Cancer Cell|June 15, 2010
Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cellsAnn Mullally, Steven W Lane, Brian Ball, et al.Blood|March 16, 2007
A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemiaTing-lei Gu, Thomas Mercher, Jeffrey W Tyner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 25, 2010
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3Thomas Fischer, Richard M Stone, Daniel J Deangelo, et al.The Journal of Experimental Medicine|February 1, 2006
Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutationsHanna S Radomska, Daniela S Bassères, Rui Zheng, et al.Plos Medicine|July 13, 2006
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaYana Pikman, Benjamin H Lee, Thomas Mercher, et al.Pageof 18